Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary

Why It Matters

By moving to NASDAQ and accelerating its Phase III program, NerveGen aims to unlock U.S. funding and validate a novel neuro‑reparative therapy, potentially reshaping treatment options for spinal‑cord injury and related neuro‑trauma.

Key Takeaways

• Transitioned NerveGen from TSX to NASDAQ to boost visibility.
• CEO Adam Rogers leverages prior CEO experience to accelerate Phase III launch.
• Early SCI trial data shows promising safety and efficacy signals.
• Hiring regulatory experts like Shamine Ruff strengthens FDA navigation.
• Strategic focus on neuro‑trauma market expands beyond spinal cord injury.

Summary

The interview with NerveGen’s CEO Adam Rogers and adviser Rich McCary centers on the company’s new growth strategy as it prepares for a pivotal Phase III trial of its peptide therapy NVG291 for spinal‑cord injury. Rogers, a former biotech founder who sold Himera to Johnson & Johnson, took the helm last summer and immediately set out to raise the company’s profile and operational agility.

Key actions include moving the stock listing from the Toronto Stock Exchange to NASDAQ, a move designed to attract U.S. analysts and institutional investors. Early data from the 1B/2A SCI study demonstrated encouraging safety and functional outcomes, giving the board confidence to push toward a large‑scale trial. The leadership also prioritized talent acquisition, hiring seasoned regulatory professionals such as Shamine Ruff to navigate the FDA’s orphan‑drug pathway.

Rogers cites mentorship from his father‑in‑law, Reebok founder Paul Fireman, emphasizing the value of listening and decisive decision‑making. Rich McCary’s background in RNA therapeutics and his personal drive after his mother’s Alzheimer’s diagnosis underscore the team’s deep scientific commitment and entrepreneurial grit.

The strategic shift positions NerveGen to secure U.S. capital, broaden its addressable neuro‑trauma market, and potentially set a new standard for reparative peptide therapies. Success could catalyze further investment in non‑genetic, injury‑model‑based drug platforms across the biotech sector.

Original Description

On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries. Adam talks about his strategy for the company after becoming CEO last July, including moving company trading from Canada's TSX Venture Exchange to the NASDAQ for better visibility, and making key hires for growth. Rich talks about his early work in RNA therapeutics as an advisor at Sarepta, cofounding Synaptica Therapeutics, and bringing Adam to NervGen. They also talk about engaging with the FDA on endpoints for NVG-291's Phase 3 trial, and the broader opportunity in neurotrauma.

Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com

---

#businessofbiotech #biopharma #biotech

Subscribe to the podcast:

Apple - https://podcasts.apple.com/us/podcast/business-of-biotech/id1508008606?uo=4

Spotify - https://open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA

YouTube - https://www.youtube.com/playlist?list=PLFXsCNKV78rWNPmqIA8b2dKYLPYYv28wb